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7RESEARCH ARTICLE Open AccessIntravitreal ranibizumab monotherapy to treat
retinopathy of prematurity zone II, stage 3 with
plus disease
Marcel N Menke1,5*, Carsten Framme1,2, Mathias Nelle3, Markus R Berger3, Veit Sturm4 and Sebastian Wolf1Abstract
Background: Treatment of retinopathy of prematurity (ROP) stage 3 plus with bevacizumab is still very
controversial. We report the outcome of 6 eyes of 4 premature infants with ROP stage 3 plus disease treated with
ranibizumab monotherapy.
Methods: Six eyes of 4 premature infants with threshold ROP 3 plus disease in zone II, were treated with one
intravitreal injection of 0.03 ml ranibizumab. No prior laser or other intravitreal therapy was done. Fundus
examination was performed prior to the intervention and at each follow-up visit. Changes in various mean vital
parameters one week post intervention compared to one week pre-intervention were assessed.
Results: The gestational age (GA) of patient 1, 2, 3, and 4 at birth was 24 5/7, 24 5/7, 24 4/7, and 26 1/7 weeks,
respectively. The birth weight was 500 grams, 450 grams, 665 grams, and 745 grams, respectively. The GA at the
date of treatment ranged from 34 3/7 to 38 6/7 weeks. In one infant, upper air way infection was observed 2 days
post injection of the second eye. Three eyes required paracentesis to reduce the intraocular pressure after injection
and to restore central artery perfusion. After six months, all eyes showed complete retinal vascularisation without
any signs of disease recurrence.
Conclusions: Treatment of ROP 3 plus disease with intravitreal ranibizumab was effective in all cases and should be
considered for treatment. One infant developed an upper air way infection suspicious for nasopharyngitis, which
might be a possible side effect of ranibizumab. Another frequent complication was intraocular pressure rise after
injection. More patients with longer follow-up duration are mandatory to confirm the safety and efficacy of this
treatment.
Trial registration number: NCT02164604; Date of registration: 13.06.2014
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Retinopathy of prematurity (ROP) is a neovascular ret-
inal disorder of premature born children, characterized
by the development of retinal neovascularisation, macu-
lar dragging and eventually retinal detachment. ROP is a
leading cause for childhood blindness, especially in de-
veloping countries [1]. Vascular endothelial growth fac-
tor (VEGF) plays an important role in the development* Correspondence: marcel.menke@ksa.ch
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unless otherwise stated.of the disease. VEGF production is triggered by the avas-
cular part of the retina and accumulation of VEGF even-
tually leads to neovascularisation and retinal detachment
if not treated in time [2]. Currently, near-confluent laser
therapy is recommended for treatment of the outer,
avascular retina to destroy the cells that produce VEGF
[3].
Recently, the BEAT ROP study tested the efficacy of
intravitreal bevacizumab (Roche AG, Basel, Switzerland)
for stage 3 plus ROP in a prospective, controlled, ran-
domized, stratified, multicenter trial [4]. Authors found
that bevacizumab showed a significant benefit for Zone I
but not Zone II disease, with continuation of peripheralThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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concluded that safety could not be assessed due to the
small sample size. Other authors raised concerns re-
garding the results of the BEAT ROP study [5]. Visual
outcomes were not reported in the BEAT ROP trial. In
addition, recurrence of ROP may have occurred after
the study end point since late recurrence of ROP after
bevacizumab treatment has been reported [4]. Also the
dose used in the BEAT-ROP trial might have been too
high [5].
Sato et al. could show that bevacizumab escapes from
the vitreous into the general circulation and reduces sys-
temic VEGF levels for weeks to months in premature in-
fants [6]. In contrast, Carneiro et al. showed that
ranibizumab does not alter systemic VEGF levels in
adults [7]. Bearing this in mind together with a shorter
half-life of ranibizumab in human nonvitrectomized eyes
(7.15 days versus 9.82 days) we suspected a better safety
profile for ranibizumab to treat stage 3 plus ROP [8].
The aim of this study was to demonstrate the effective-
ness of intravitreal ranibizumab to treat ROP stage 3
plus disease. Here we present the outcome of 6 eyes.
Methods
Six eyes of 4 children with confirmed ROP stage 3 plus
in Zone II have been included. The diagnosis was con-
firmed by indirect ophthalmoscopy and scleral indenta-
tion. Parents were informed regarding the disease and
treatment options. Laser-photocoagulation of the avas-
cular retina was suggested. Alternatively, one intravitreal
injection with 0.03 ml ranibizumab was offered for treat-
ment. Parents decided for their children to receive intra-
vitreal ranibizumab in these cases and signed an
informed consent before the procedure. The Cantonal
Ethics Committee of Berne was informed prior to treat-
ment and approved therapy. No prior laser or other
intravitreal therapy was performed. The injection pro-
cedure was planned in collaboration with the
Department of Neonatology and was performed in a
special intervention room at the neonatology unit.
Patients were analgosedated, intubation was performed
based on the decision of the neonatology team if the in-
fant was unstable due to general clinical condition. All
infants were continuously monitored during and after
the procedure. Ranibizumab was injected with a 30-
gauge needle through the conjunctiva approximately
1.5 mm behind the nasal limbus according to a proced-
ure that was published previously using bevacizumab in-
stead of ranibizumab [9]. Disinfection of the injection
side was done with polyhexamethylene biguamide (Poly-
hexanide, based on Lavasept® solution, B Braun Melsungen
AG, Melsungen, Germany) eyedrops. Skin disinfection
was done with Octenidindihydro-chlorid (Octenisept,
Steinberg Pharma AG, Winterthur, Switzerland). Bothagents were used to avoid iodine absorption which could
be problematic in premature infants. The eye was stabi-
lized with a toothed forceps while the dose of 0.03 ml rani-
bizumab was injected. After injection, the intraocular
pressure was assessed by bulbus palpation. Central artery
perfusion was checked by indirect ophthalmoscopy imme-
diately after injection. If necessary, paracentesis was per-
formed to release pressure after intravitreal injection.
Photographic documentation was done with a HEINE
Video OMEGA® 2C indirect ophthalmoscope (Heine
Optotechnik, Herrsching, Germany) An ophthalmic anti-
biotic eye drop (Tobrex eye drops; 3 mg Tobramycin/
1 ml, Alcon Grieshaber AG, Schaffhausen, Switzerland)
was prescribed for the treated eye to begin immediately
and be continued 4 times a day for 3 days. All patients
were re-examined the following day, three days after treat-
ment, one week after treatment, and then depending on
regression of ROP and status of vascularisation of the
avascular retina. In addition, patients were continuously
monitored in the neonatology unit for possible side effects
of the treatment.
Results
Female patient 1 had a gestational age (GA) of 24 5/
7 weeks at birth and weight 500 grams. At the left eye
severe ROP 3 plus in zone II over 7 clock hours was di-
agnosed at gestational week 32 6/7. OS was injected
24 hours after diagnosis. OD was observed having ROP
3 without plus disease in zone II. One week post treat-
ment plus disease showed clear regression in the left
eye. Unfortunately, 14 days after treating OS, the right
eye progressed to ROP 3 plus disease over 6 clock hours
(gestational age 37 3/7) and therefore an injection was
performed the same day of diagnosis. Immediately after
the injection procedure anterior chamber paracentesis
was required due to high intraocular pressure with poor
central artery perfusion observed with indirect ophthal-
mology. Three days after injecting OD the patient devel-
oped moderate upper airway infection suspicious for
nasopharyngitis that was tested positive for Klebsiella
pneumonia and successfully treated with antibiotics.
One week past treatment the neovascularisations
showed clear regression and plus disease was absent in
both eyes. Three months past the injection in OS, vascu-
larisation of the peripheral retina was complete in OD
but still incomplete in OS. 6 months after treatment vas-
cularisation was complete in both eyes without recur-
rence of ROP.
Patient 2 is the twin sister of patient 1 with a birth
weight of 450 grams. Her right eye required treatment at
GA of 34 3/7 weeks for severe ROP 3 plus disease in
zone II over 8 clock hours. After injection, anterior para-
centesis was required to reduce pressure since central
artery perfusion was poor directly after injection. One
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6 months follow up, vascularisation was complete with
no recurrence of ROP. Figure 1 shows fundus findings
before injection, and 1 week and 6 months after
treatment.
Female patient 3 had a GA of 24 4/7 weeks at birth
and weight 665 grams. The right eye received treatment
for ROP 3 over 6 clock hours with plus disease in Zone
II at GA of 34 4/7 weeks without any occurring compli-
cation. The left eye also showed ROP 3 over 6 clock
hours with plus disease in Zone II and required treat-
ment at GA 35 5/7 weeks. Also anterior chamber para-
centesis was required due to high intraocular pressure in
OS. One week after intervention, plus disease has disap-
peared in both eyes. At 3 months follow up, vascularisa-
tion was incomplete in OD with ROP 1 without plus
disease in Zone II. Vascularisation of OS was complete.
At 6 months endpoint, vascularisation was complete in
both eyes without recurrence of ROP.Figure 1 Funduspictures taken from patient 4. Top: Funduscopic
findings before ranibizumab injections show plus disease with
tortuous, dilated blood vessels. On the right, the ridge with
neovascularisations can be appreciated under sclera indentation.
Middle: One week post-injection plus disease has almost completely
disappeared. Bottom: Six month post treatment, retinal vascularisation
is complete without recurrence of ROP.Female patient 4 had a GA of 26 1/7 weeks at birth
and weight 745 grams. The left eye showed ROP 3 over
9 clock hours in Zone II with plus disease and required
treatment at GA of 38 6/7 weeks without any occurring
complication. Complete regression of plus disease was
seen 1 week post injection. At 3 and 6 months follow
up, vascularisation was complete with no recurrence of
ROP.
Table 1 shows baseline data of all patients and con-
comitant diseases. Main vital parameters such as mean
systolic and diastolic blood pressure, mean pulse rate,
and required oxygen therapy (mean FiO2) have been
monitored. In addition, patients were monitored for dips
of oxygen saturation and lowest values were recorded
for each day. Vital parameters one week before treat-
ment were compared with values 1 week after injection.
Findings are presented in Table 2. Minimal oxygen sat-
uration levels (dips in O2 saturation as a sign for respira-
tory stability) were lower 1 week before the treatment (mean
lowest O2 saturation pre-treatment was 61.89 ± 2.63%)
compared to 1 week after treatment (mean lowest
O2 saturation post-treatment was 70.54 ± 1.12%;
p = 0.0037). All other vital parameters in exception of
respiratory stability, showed no significant difference
after treatment with ranibizumab.
Discussion
Intravitreal bevacizumab has become increasingly popu-
lar to treat ROP 3 plus disease and zone one disease. In
2007 first case reports were published, showing fast re-
gression of ROP after single injections of the drug either
as single line treatment or in combination with laser
[10,11]. The observation of fast ROP regression and
complete retinal vascularisation after anti-VEGF injec-
tion led to an increasing popularity of this treatment op-
tion. Multiple reviews have been published discussing
the use of bevacizumab in ROP even before the first ran-
domized prospective study data of the BEAT ROP trial
became available [12-14]. The BEAT ROP trial showed
favorable results of bevacizumab in Zone I but not in
Zone II disease compared to laser therapy [4]. Although
it was the first prospective, randomized trial, the results
raised several concerns. Study population was too small
to assess safety of bevacizumab treatment. The mortality
of children was 6.6% in the bevacizumab treated group
vs. 2.6% in the laser group. Although the difference was
not statistically significant, mortality needs to be closely
monitored in these patients [5]. In addition, little is
known regarding the functional outcome of eyes treated
with intravitreal bevacizumab.
These concerns led us to the idea of treating severe
ROP with intravitreal ranibizumab. Ranibizumab seems
to have a shorter half-life in human non-vitrectomized
eyes (7.15 days versus 9.82 days of bevacizumab) which
Table 1 Baseline characteristics and concomitant diseases
Patient GA at birth AA at injection Birthweight Comcomitant diseases
1 24 5/7 OD: 37 3/7 500 g apnea and bradycardia syndrome, persisten ductus arteriosus, RDS, pneumonia, kidney insufficiency,
arterial hypotension, hyperbilirubinemia, anemia
OS: 32 6/7
2 24 5/7 OD 34 3/7 450 g apnea and bradycardia syndrome, persisten ductus arteriosus, RDS, pneumonia, arterial hypotension,
hyperbilirubinemia, anemia, hernia inguinalis, sepsis, neutropenia
3 24 4/7 OD: 34 4/7 665 g apnea and bradycardia syndrome, , RDS, neonatal infection, urinary tract infection, intracerebral
hemorrhage pneumonia, arterial hypotension, hyperbilirubinemia, anemia, bronchopulmonary
dysplasia, kidney insufficiencyOS: 35 5/7
4 26 1/7 OS: 38 6/7 745 g apnea and bradycardia syndrome, RDS, hyperbilirubinemia, anemia
GA = gestational age; RDS = respiratory distress syndrome; AA = Adjusted age.
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the lowest systemic concentration for the shortest pos-
sible duration [8]. It has been shown, that ranibizumab
does not alter systemic VEGF levels in adults [7]. How-
ever, recently Hoerster and colleagues testes serum
VEGF levels in a premature infant after one injection
of ranibizumab to treat ROP 3 plus in zone I. They
found suppressed systemic VEGF levels below detec-
tion limit for about 2 weeks post-injection. This sup-
pression might be explained by an impaired blood-
retina barrier of the immature retina at this age, as
ranibizumab does not seem to change systemic VEGF
levels in adults. Hoerster et al. found that four weeks
after bilateral treatment, systemic VEGF levels
returned to normal values [15]. In a case series of 11
eyes treated with bevacizumab, systemic VEGF levels
were suppressed for at least 7 weeks post-injection. In
addition, Sato et al. measured serum VEGF level in in-
fants after intravitreal bevacizumab injection and
found systemic reduction of VEGF levels for at least
2 weeks after injection [6]. This data points in the dir-
ection of a better safety profile for ranibizumab [16].
One can assume that ranibizumab shows less systemic
drug activity after intravitreal injection and this might
be a possible explanation why 2 of our patients
required bilateral injections within a short period of
few weeks. With bevacizumab, improvement of the
untreated partner eye has been reported in a case of anTable 2 Vital parameters one week before and after ranibizum
1 week pre-injection
Mean systolic blood pressure 61.07 ± 1.5 mmHg
Mean diastolic blood pressure 31.43 ± 1.1 mmHg
Mean heart rate 154.9 ± 1.4
Mean respiratory frequency 54.46 ± 0.9
Mean FiO2 21.89 ± 1.8%
mean lowest O2 saturation 61.89 ± 2.6%
ns = not significant.8 year-old girl with uveitic cystic macular edema indi-
cating that the systemic drug action might even be
strong enough to “treat” the partner eye at least in
older children or adults [17].
In our study group all eyes showed rapid regression of
ROP after single injection of 0.3 mg ranibizumab. No
late recurrence of ROP was seen over a period of
6 months and all patients finally gained complete retinal
vascularization. The treatment procedure appears to be
safe but short-term IOP increase is frequent (50% of our
cases). In all cases of increased IOP, indirect ophthal-
moscopy after injection revealed poor central artery per-
fusion which let us performing paracentesis to reduce
pressure. After this procedure, central artery perfusion
improved immediately. To our knowledge, no studies in-
vestigated IOP increase after anti-VEGF injection in in-
fants. However, transient or even sustained IOP
elevation after anti-VEGF injection in adult patients is
common knowledge and well described [18-20].
The injected volume plays an important role in this IOP
matter. In our cases 0.03 ml (0.3 mg) ranibizumab was
injected. There is still ongoing discussion, how much anti-
VEGF drug is required to treat ROP sufficiently with one
single injection. Sears et al. estimated that approximately
0.5-1.0 mg of bevacizumab is 10000 times the concentra-
tion needed to neutralize the highest measured concentra-
tion of VEGF. [21] Other reports have shown that lower
doses of bevacizumab (0.375 g) achieved regression ofab injection
1 week post-injection p-value
64.39 ± 1.1 mmHg ns
32.61 ± 1.2 mmHg ns
153.9 ± 1.9 ns
52.46 ± 1.1 ns
22.39 ± 2.1% ns
70.54 ± 1.1% 0.0037
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was half the adult dose. However, the vitreous volume of
an infant at 34 weeks is less (1.6 ml vs. 4.0 ml), as is the
retinal surface area (450 mm2 vs. 1240 mm2). In addition,
the body weight is about one-fiftieth of an adult person
[5]. Most likely the ranibizumab dose used in our cases
was unnecessarily high but currently there is no valid dos-
age data available and the risk of under-treatment should
be avoided since intravitreal injections are invasive proce-
dures that should not be repeated if not necessary.
Few other reports have been published using ranibizu-
mab for ROP treatment. Lin C.J. et al. report a case of
an extreme low-birth-weight infant that was previously
unsuccessfully treated with intravitreal bevacizumab and
laser for aggressive zone I disease. After one injection of
0.25 mg ranibizumab, ROP disappeared completely and
the retina developed complete vascularisation [23]. The
same group published a series of cases of ROP 3 treated
with ranibizumab and showed good response to treat-
ment with no short-term systemic side effects or major
ocular side effects [24]. Castellanos M.A. et al. presented
a case series of six eyes treated with one injection of
ranibizumab and followed patients over 3 years. All pa-
tients gained complete retinal vascularisation with full
regression of ROP. After 3 years, average visual acuity
(snellen equivalent) was 20/30, which implies normal
ocular growth and function after ranibizumab treatment
in these cases [25]. Mota A. et al. used ranibizumab in
combination with laser to successfully treat zone I dis-
ease in 2 cases. No systemic or ocular adverse effects
have been observed [26].
In our case series, upper airway infection suspicious
for nasopharyngitis has been observed in one patient
after injection as a possible side effect of ranibizumab
treatment. Nasopharyngitis has been observed in 12.5 to
16.4% of age-related macular degeneration cases that
were treated with ranibizumab in three phase III studies
[27-29]. Rather trivial in adult patients, nasopharyngitis
might be a severe complication in premature born chil-
dren with pre-existing breathing problems due to a re-
spiratory distress syndrome.
In addition, several vital parameters have been ob-
served one week before and after treatment. No signifi-
cant change of pulse rate, respiratory rate, systolic and
diastolic blood pressure and required mean FiO2 was
found in our patient group. Only minimal oxygen satur-
ation levels (dips in O2 saturation) were significantly
lower 1 week before the treatment (mean lowest O2 sat-
uration pre-treatment was 61.89 ± 2.63%) compared to
1 week after treatment (mean lowest O2 saturation post-
treatment was 70.54 ± 1.12%; p = 0.0037). These findings
are most likely related to the fact that infants simply be-
come older and that their respiratory distress syndrome
or bronchopulmonary dysplasia further improved.There is the limitation that only 4 patients have been
treated. Beside the small sample size, this case series has
further limitations. The observation period has only
been 6 months. No visual acuity values have been re-
ported. In addition, no patients with zone 1 disease have
been included in this case series. This was the group that
showed most benefit in the BEAT-ROP trial. Further
prospective studies with larger study populations are re-
quired to evaluate the effectiveness and safety of ranibi-
zumab for ROP treatment. Our case series has not the
power to assess safety of ranibizumab treatment. Fun-
duscopy showed that all patients developed complete
retinal vascularisation after treatment, but since no
fluorescein angiography was performed, it remains un-
known if vascularisation was normal or abnormal. Based
on the observations of the BEAT-ROP trial and our own
observations, follow up should be at least every 2–3
weeks until vascularization is complete, approximately
20+ weeks following the last antiVEGF injection.Conclusions
In conclusion, one single injection of ranibizumab was
effective in treating ROP 3 plus disease in zone 2 in all
cases without showing late recurrence of ROP. Treat-
ment led to complete retinal vascularisation within the
follow up period of 6 months. Preterm infants treated
with intravitreal ranibizumab might have better outcome
than preterm infants receiving conventional laser ther-
apy since peripheral retinal destruction was suggested as
the primary cause of visual field loss and development of
high myopia [30]. There was no significant negative ef-
fect on basic vital parameters related directly to the
treatment. Nasopharyngitis has been observed in one
case as a possible side effect of treatment as well as fre-
quent post-injection increase of intraocular pressure.
Further prospective studies with larger study population
are required to evaluate the effectiveness and safety of
ranibizumab for ROP treatment.Ethics approval
IRB (Cantonal Ethics Committee of Berne, Switzerland)
approval for this work was obtained.
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